1
Beije, Nick, Kraan, Jaco, Taal, Walter, van der Holt, Ronnie, Oosterkamp, HM, Walenkamp, AM, Beerepoot, L, Hanse, M, van Linde, ME, Otten, A, Vernhout, René, de Vos, FYF, Gratama, Jan willem, Sleijfer, Stefan, van den Bent, Martin
Veröffentlicht in: Beije , N , Kraan , J , Taal , W , van der Holt , R , Oosterkamp , HM , Walenkamp , AM , Beerepoot , L , Hanse , M , van Linde , ME , Otten , A , Vernhout , R , de Vos , FYF , Gratama , J W , Sleijfer , S & van den Bent , M 2015 , ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ' , British Journal of Cancer , vol. 113 , no. 2 , pp. 226-231 . https://doi.org/10.1038/bjc.2015.191;
2015
Veröffentlicht in: Beije , N , Kraan , J , Taal , W , van der Holt , R , Oosterkamp , HM , Walenkamp , AM , Beerepoot , L , Hanse , M , van Linde , ME , Otten , A , Vernhout , R , de Vos , FYF , Gratama , J W , Sleijfer , S & van den Bent , M 2015 , ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ' , British Journal of Cancer , vol. 113 , no. 2 , pp. 226-231 . https://doi.org/10.1038/bjc.2015.191;
2015